Lorus Therapeutics Announces Allowance of United States Patent for Cancer Drug LOR-2040 in the Treatment of Acute …
Lorus Therapeutics Announces Allowance of United States Patent for Cancer Drug LOR-2040 in the Treatment of Acute …
TORONTO, ONTARIO– – Lorus Therapeutics Inc. , a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies for the management of cancer, today announced that the United States Patent and Trademark Office has allowed a new patent for the Company’s lead clinical stage cancer drug LOR-2040 in the treatment of Acute Myeloid Leukemia .
Read more on CCNMatthews via Yahoo! Finance
Categories: Breast Cancer Information Tags: acute, Allowance, Announces, cancer, drug, LOR2040, Lorus, Patent, States, Therapeutics', Treatment, United
Eisai enters strategic drug discovery collaboration with FORMA Therapeutics
Eisai enters strategic drug discovery collaboration with FORMA Therapeutics
Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., and FORMA Therapeutics announced today that the two companies have signed a strategic drug discovery collaboration.
Read more on News-Medical-Net
Categories: Breast Cancer Pain Tags: collaboration, Discovery, drug, Eisai, Enters, FORMA, strategic, Therapeutics'
Allos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO Congress
Allos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO Congress
WESTMINSTER, Colo.–(BUSINESS WIRE)–Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that results from the Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) will be presented at the 35th European Society of Medical Oncology (ESMO) Congress — Milan, Italy from October 8-12, 2010 …
Read more on Business Wire
Categories: High Risk Breast Cancer Tags: 35th, Allos, Announces, Congress, Data, ESMO, FOLOTYN®, Presentation, Therapeutics'
Allos Therapeutics Announces Topline Results From Phase 2b Study Of FOLOTYN In Patients With Advanced Non-Small Cell …
Allos Therapeutics Announces Topline Results From Phase 2b Study Of FOLOTYN In Patients With Advanced Non-Small Cell …
Allos Therapeutics, Inc. (NASDAQ:ALTH) announced topline results from the Company’s randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to …
Read more on Medical News Today
Categories: Breast Cancer Tumor Tags: advanced, Allos, Announces, Cell, FOLOTYN, From, NonSmall, Patients, Phase, Results, Study, Therapeutics', Topline
Novelos Therapeutics Announces Positive Phase 2 Results in NOV-002 Neoadjuvant Breast Cancer Trial at Sylvester …
Novelos Therapeutics Announces Positive Phase 2 Results in NOV-002 Neoadjuvant Breast Cancer Trial at Sylvester …
NEWTON, Mass.—-Novelos Therapeutics, Inc. , a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester …
Read more on Business Wire via Yahoo! Finance
Categories: Breast Cancer Doctors Tags: Announces, breast, cancer, Neoadjuvant, NOV002, Novelos, Phase, positive, Results, Sylvester, Therapeutics', Trial